We are committed to advancing innovative combinatorial immunotherapies that harness the power of the immune system.
Our mission is to transform and extend patients’ lives by accelerating the development of novel immunotherapies through a streamlined, cost-effective, and data-driven approach. We believe the future of oncology lies in targeted, mechanism-informed combinations that unlock the therapeutic potential of the innate immune system. Traditional biotech models are often slow, high-risk, and resource-intensive. Daelion takes a different path—focusing on early clinical proof-of-concept studies guided by robust translational science to minimize time, risk, and cost while maximizing patient impact.
Our Commitment to Immunotherapy Innovation
Daelion Therapeutics was founded to advance the clinical development of Odetiglucan (Odeti)—a first-in-class immunotherapy with compelling clinical potential. Leveraging Odeti’s capacity to activate innate immune pathways, we are developing novel combination strategies designed to overcome resistance mechanisms and extend the durability of cancer immunotherapy responses.
Our team is uniquely positioned to harness emerging insights in myeloid biology and tumor-immune interactions, translating these discoveries into rationally designed clinical studies that deliver meaningful benefit to patients.
